Malaria progress has levelled but new drugs are due

25 Apr 2018

George Jagoe

With progress stalling in the treatment of malaria, the development of new medicines to prevent and treat it are a top priority if we are to prevent a backward slide to the dark days of the ’90s.

Less than 20 years ago, the situation for those living in countries worst affected by malaria was dire. Existing medications had become wooden bullets in the clinical armoury because of drug resistance. At that time, clinicians expressed frustration and despair at their inability to offer effective treatments to sick patients. The vast majority of the time, those clinicians were coping with very ill young children whose immature immune systems leave them most vulnerable to malaria.

Beginning in the mid-2000s, thanks to widespread adoption of new artemisnin-based medicines and a significant increase in R&D investments, improvements in antimalarial treatments have contributed to large reductions in malaria-related mortality rates.

Over the last decade, progress in drug treatments for children between 0–5 years (along with other interventions) have resulted in millions of lives saved....

Read the full article on The Fight Against Malaria website

This article is part of the Fight Against Malaria campaign, published on World Malaria Day by Mediaplanet.